Remembering John Lewis and Understanding Pancreatic Cancer

What he announced

John Lewis was an original Freedom Rider, chairman of the Student Nonviolent Coordinating Committee, an organizer of the Selma march, and a congressman from Georgia for 17 terms.

He announced his own diagnosis publicly at the end of December 2019. The Pancreatic Cancer Action Network records that he disclosed it on December 30, 2019, and that the cancer was stage IV. He died on July 17, 2020, at age 80.

He chose to make the diagnosis public. Nothing beyond that was released about his treatment, and nothing further is claimed here. What follows is what stage IV pancreatic cancer actually involves.

What stage IV means here

Stage IV means the cancer has reached a distant organ. For pancreatic cancer that is usually the liver, sometimes the lungs or the lining of the abdomen.

The practical consequence is that surgery is no longer the route. Removing the primary tumor does not help when disease is established elsewhere. Treatment shifts to drugs that circulate everywhere, plus specific measures for symptoms.

This is the common situation, not the exception. SEER, the cancer surveillance program run by NCI, reports that 51% of pancreatic cancers are already distant when found, and only 15% are still localized. The median age at diagnosis is 71.

An uneven burden

The numbers differ by group, and the gap is consistent.

SEER puts the rate of new pancreatic cancer cases at 15.7 per 100,000 among men overall, rising to 18.0 among non-Hispanic Black men, against 16.3 among non-Hispanic White men. Among women the overall rate is 12.4, rising to 15.4 among non-Hispanic Black women, against 12.3 among non-Hispanic White women.

Death rates follow. Among men, 12.9 per 100,000 overall, 15.0 among non-Hispanic Black men. Among women, 9.9 overall and 12.3 among non-Hispanic Black women.

These are population figures. They say nothing about any individual, including John Lewis. They do say that a Black patient reporting vague abdominal symptoms is starting from a higher baseline risk, which is a reason for clinicians and patients alike to push for answers rather than wait.

The inherited fraction

Some pancreatic cancers run in families. The National Cancer Institute (NCI) lists inherited changes in BRCA1, BRCA2, PALB2, and ATM among the risk factors, alongside smoking, obesity, chronic pancreatitis, and family history.

The scale is not trivial. In the POLO trial, investigators screened 3,315 patients with metastatic pancreatic cancer and identified 247 with a germline BRCA1 or BRCA2 variant.

This matters for two reasons. It changes treatment, and it changes what relatives should know. If you or a family member has pancreatic cancer, ask whether germline genetic testing was offered.

First-line treatment, and the tradeoff

Two regimens dominate, and choosing between them is largely about how well someone is functioning day to day.

FOLFIRINOX combines four drugs: oxaliplatin, irinotecan, leucovorin, and fluorouracil. In a trial of 342 patients with metastatic disease, all of whom were fully or nearly fully active, median overall survival was 11.1 months with FOLFIRINOX against 6.8 months with gemcitabine alone. Median progression-free survival was 6.4 months against 3.3 months.

Gemcitabine plus nab-paclitaxel is the other standard. In a trial of 861 patients, median overall survival was 8.5 months against 6.7 months for gemcitabine alone.

Both are harder on the body than gemcitabine alone. Febrile neutropenia, meaning fever with a dangerously low white cell count, hit 5.4% on FOLFIRINOX. On gemcitabine with nab-paclitaxel, grade 3 side effects included neutropenia in 38%, fatigue in 17%, and nerve damage in 17%.

Here is the counterintuitive finding. At six months, 31% of the FOLFIRINOX group had a definite worsening of quality of life, compared with 66% of the gemcitabine-alone group. The more intensive regimen preserved quality of life better, because controlling the cancer mattered more than avoiding the drug side effects.

For people with a germline BRCA1 or BRCA2 variant whose disease has responded to platinum-based chemotherapy for more than four months, NCI notes that olaparib, a PARP inhibitor taken as a tablet, can be considered as maintenance therapy.

Get help now

If you have pancreatic cancer or are being investigated for it, seek urgent care for:

• Yellowing of the eyes or skin, dark urine, or pale stools
• Fever above 100.4°F while receiving chemotherapy, which is always an emergency
• Fever with yellowing, which can mean an infected bile duct
• Vomiting that will not stop, or the inability to keep fluids down

Contact your team within a day or two for:

• Pain that is not controlled by the current medication
• Greasy, floating stools with ongoing weight loss, which may need pancreatic enzyme replacement
• New leg swelling or calf pain, since this cancer raises the risk of blood clots

Progress that is real, and slow

SEER's own long record shows the shift. In 1975, five-year relative survival for pancreatic cancer was about 3%. For people diagnosed between 2016 and 2022 it stands at 13.7%.

That is a fourfold improvement and still the lowest figure among common cancers. For 2026, the American Cancer Society projects about 67,530 new cases and 52,740 deaths, a figure SEER publishes.

There is one more thing worth saying about a stage IV diagnosis. NCI states that clinical trials should be considered, and that palliative therapies can be used at any stage of the disease. Palliative care is not a last resort. It runs alongside treatment and is aimed at pain, appetite, energy, and function.

Every number on this page describes groups of people studied in the past. None of them forecasts one person's course.

Sources

• https://www.cancer.gov/types/pancreatic/hp/pancreatic-treatment-pdq
• https://seer.cancer.gov/statfacts/html/pancreas.html
• https://www.history.com/this-day-in-history/july-17/congressman-john-lewis-dies
• https://pancan.org/news/pancan-mourns-death-of-civil-rights-icon-john-lewis/